Advertisement

Topics

Latest "Cerus" News Stories

16:37 EST 16th January 2018 | BioPortfolio

Here are the most relevant search results for "Cerus" found in our extensive news archives from over 250 global news sources.

More Information about Cerus on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cerus for you to read. Along with our medical data and news we also list Cerus Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cerus Companies for you to search.

Showing "Cerus" News Articles, all 23

Monday 8th January 2018

Cerus Corporation Announces Preliminary Product Revenue Results for Fourth Quarter and Full Year 2017

Record preliminary product revenue reported along with expected strong 2018 growth Cerus Corporation (NASDAQ: CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2017 and provided 2018 product revenue guidance. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2017 was ...


Wednesday 3rd January 2018

FLX Bio Appoints Dirk G. Brockstedt, Ph.D., as Senior Vice President of Biology

FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small molecule drugs to activate the immune system against cancer, today announced the appointment of industry veteran Dirk G. Brockstedt, Ph.D., to the position of Senior Vice President of Biology. “Dirk brings a wealth of experience in immuno-oncology a...

Tuesday 7th November 2017

Cerus Corporation Receives IDE Approval to Initiate Phase III ReCePI Study

ReCePI study designed to evaluate the efficacy of the INTERCEPT Blood System for Red Blood Cells in patients undergoing complex cardiac surgery Cerus Corporation (NASDAQ: CERS) today announced it has received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate ReCePI (A Randomized, Double-Blin...


Monday 6th November 2017

Technical Insights on Biotech Stocks -- Cara Therapeutics, Catabasis Pharma, Cerus, and Genocea ...

NEW YORK, Nov. 6, 2017/PRNewswire/ -- If you want a Stock Review on CARA, CATB, CERS, or GNCA then come over to http://dailystocktracker.com/register/ Read more...

Thursday 2nd November 2017

Cerus' (CERS) CEO Obi Greenman on Q3 2017 Results - Earnings Call Transcript

Cerus Corporation Reports Third Quarter 2017 Results

Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2017. Recent developments include: Announced national German reimbursement for pathogen-inactivated platelets starting January 1, 2018. Germany is the largest platelet market in Europe with approximately 575,000 units m...

Tuesday 31st October 2017

Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in Italy

Agreement covers complete INTERCEPT product line:platelets, plasma, and red blood cells. Cerus Corporation (NASDAQ:CERS) announced today that it has entered into an agreement with Kedrion Biopharma to distribute the full complement of INTERCEPT Blood System products in Italy. Kedrion Biopharma will initially distribute INTERCEPT for platelets...

Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System ...

Read more...

Monday 30th October 2017

Cerus Announces Agreement with Transfusion Center of the Community of Madrid

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a supply agreement with Centro de Transfusión de la Comunidad de Madrid (CTCM) for the INTERCEPT Blood System for platelets. "We are pleased to work with CTCM in providing INTERCEPT Platelets to enhance the safety of blood components. As one of the largest blood banks in Spa...

Monday 23rd October 2017

Cerus Announces National German Reimbursement for Pathogen Inactivated Platelets

Cerus Corporation (NASDAQ:CERS) announced today that the Institute for the Hospital Remuneration System (Institut für das Entgeltsystem im Krankenhaus, or InEK) in Germany will include pathogen-inactivated platelets for national reimbursement starting January 1, 2018. Pathogen-inactivated platelets will be reimbursed through ZE (Zusatzentgelte) codes 164 ...

Thursday 19th October 2017

Cerus to Release Third Quarter 2017 Results on November 2, 2017

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter results will be released on Thursday, November 2, 2017, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the company’s financial results and provide a general business overview and ...

Thursday 5th October 2017

Cerus Announces First Biologics License Application Approval for U.S. Blood Center Customer

Approval allows interstate shipment of INTERCEPT Platelets Cerus Corporation (NASDAQ:CERS) announced today that Rhode Island Blood Center received approval by the U.S. Food and Drug Administration (FDA) on their Biologics License Application (BLA) requesting allowance for interstate distribution of platelets that have been pathogen-reduced with the INT...

Monday 2nd October 2017

Cerus Announces Schedule of Presentations at the 2017 AABB Annual Meeting

Cerus Corporation (NASDAQ:CERS) announced today its schedule of key events at the AABB (formerly known as the American Association of Blood Banks) Annual Meeting to be held October 7-10 in San Diego, California. Cerus will be presenting the latest clinical data while blood banks and hospitals will be publishing results from their own user experience. ...

Thursday 28th September 2017

Cerus (CERS) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

Wednesday 20th September 2017

Cerus to Present at Cantor Fitzgerald’s Annual Healthcare Conference on September 27, 2017

Cerus Corporation (NASDAQ:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 10:20 AM ET on Wednesday, September 27, 2017. A live webcast of the presentation will be available from the Investor Relations ...

Monday 11th September 2017

Cerus Corporation (CERS) Presents At 24th Annual NewsMakers in the Biotech Industry - Slideshow

Wednesday 30th August 2017

Cerus to Present at Two Upcoming Conferences

Cerus Corporation (NASDAQ:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, will present at two upcoming conferences: Baird’s 2017 Global Healthcare Conference at the InterContinental New York Barclay Hotel in New York City on September 6, 2017 at 9:40 AM ET. BioCentu...

Tuesday 22nd August 2017

Is Cerus's Intercept A Pick-6?

Monday 7th August 2017

Cerus Corp CERS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25072017] Prices from USD $250

SummaryCerus Corp Cerus is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusiontransmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for...

Sunday 6th August 2017

Cerus' (CERS) CEO Obi Greenman on Q2 2017 Results - Earnings Call Transcript

Thursday 3rd August 2017

Cerus Reports Second Quarter 2017 Results

  Life Sciences Jobs   ...

Cerus Corporation Reports Second Quarter 2017 Results

Cerus Corporation (NASDAQ: CERS) today announced financial results for the second quarter ended June 30, 2017. Recent developments include: Expanded INTERCEPT Blood Systems supply agreement with Établissement Français du Sang (EFS), the French National blood service, supporting INTERCEPT platelet production in potentially a...

Oxford Finance provides $40M amended credit facility to Cerus

Cyrus secured an amended growth capital credit facility worth $40 million from Oxford Finance.  -More- 


Quick Search
Advertisement
 

News Quicklinks